BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 15735131)

  • 1. Intrathecal mafosfamide: a preclinical pharmacology and phase I trial.
    Blaney SM; Balis FM; Berg S; Arndt CA; Heideman R; Geyer JR; Packer R; Adamson PC; Jaeckle K; Klenke R; Aikin A; Murphy R; McCully C; Poplack DG
    J Clin Oncol; 2005 Mar; 23(7):1555-63. PubMed ID: 15735131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I clinical trial of mafosfamide in infants and children aged 3 years or younger with newly diagnosed embryonal tumors: a pediatric brain tumor consortium study (PBTC-001).
    Blaney SM; Boyett J; Friedman H; Gajjar A; Geyer R; Horowtiz M; Hunt D; Kieran M; Kun L; Packer R; Phillips P; Pollack IF; Prados M; Heideman R
    J Clin Oncol; 2005 Jan; 23(3):525-31. PubMed ID: 15659498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mafosfamide: a new intra-CSF chemotherapy?
    Chamberlain MC
    J Clin Oncol; 2005 Oct; 23(30):7748-9; author reply 7749. PubMed ID: 16234539
    [No Abstract]   [Full Text] [Related]  

  • 4. Phase I trial of intrathecal spartaject busulfan in children with neoplastic meningitis: a Pediatric Brain Tumor Consortium Study (PBTC-004).
    Gururangan S; Petros WP; Poussaint TY; Hancock ML; Phillips PC; Friedman HS; Bomgaars L; Blaney SM; Kun LE; Boyett JM
    Clin Cancer Res; 2006 Mar; 12(5):1540-6. PubMed ID: 16533779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I trial of intrathecal liposomal cytarabine in children with neoplastic meningitis.
    Bomgaars L; Geyer JR; Franklin J; Dahl G; Park J; Winick NJ; Klenke R; Berg SL; Blaney SM
    J Clin Oncol; 2004 Oct; 22(19):3916-21. PubMed ID: 15459213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intrathecal 6-mercaptopurine: preclinical pharmacology, phase I/II trial, and pharmacokinetic study.
    Adamson PC; Balis FM; Arndt CA; Holcenberg JS; Narang PK; Murphy RF; Gillespie AJ; Poplack DG
    Cancer Res; 1991 Nov; 51(22):6079-83. PubMed ID: 1933871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Feasibility of long-term intraventricular therapy with mafosfamide (n = 26) and etoposide (n = 11): experience in 26 children with disseminated malignant brain tumors.
    Slavc I; Schuller E; Falger J; Günes M; Pillwein K; Czech T; Dietrich W; Rössler K; Dieckmann K; Prayer D; Hainfellner J
    J Neurooncol; 2003 Sep; 64(3):239-47. PubMed ID: 14558599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intrathecal administration of 4-hydroperoxycyclophosphamide in rhesus monkeys.
    Arndt CA; Colvin OM; Balis FM; Lester CM; Johnson G; Poplack DG
    Cancer Res; 1987 Nov; 47(22):5932-4. PubMed ID: 3664493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mafosfamide as a new anticancer agent: preclinical investigations and clinical trials.
    Mazur L; Opydo-Chanek M; Stojak M; Wojcieszek K
    Anticancer Res; 2012 Jul; 32(7):2783-9. PubMed ID: 22753738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I clinical trial of intrathecal topotecan in patients with neoplastic meningitis.
    Blaney SM; Heideman R; Berg S; Adamson P; Gillespie A; Geyer JR; Packer R; Matthay K; Jaeckle K; Cole D; Kuttesch N; Poplack DG; Balis FM
    J Clin Oncol; 2003 Jan; 21(1):143-7. PubMed ID: 12506183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebrospinal fluid pharmacokinetics of intraventricular and intravenous aziridinylbenzoquinone.
    Zimm S; Collins JM; Curt GA; O'Neill D; Poplack DG
    Cancer Res; 1984 Apr; 44(4):1698-701. PubMed ID: 6704975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intrathecal mafosfamide therapy for pediatric brain tumors with meningeal dissemination.
    Slavc I; Schuller E; Czech T; Hainfellner JA; Seidl R; Dieckmann K
    J Neurooncol; 1998; 38(2-3):213-8. PubMed ID: 9696374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of intrathecal 4-hydroperoxycyclophosphamide in a nude rat model of human neoplastic meningitis.
    Fuchs HE; Archer GE; Colvin OM; Bigner SH; Schuster JM; Fuller GN; Muhlbaier LH; Schold SC; Friedman HS; Bigner DD
    Cancer Res; 1990 Mar; 50(6):1954-9. PubMed ID: 2306744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics following intraventricular administration of chemotherapy in patients with neoplastic meningitis.
    Fleischhack G; Jaehde U; Bode U
    Clin Pharmacokinet; 2005; 44(1):1-31. PubMed ID: 15634030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma and cerebrospinal fluid pharmacokinetic study of BNP1350 in nonhuman primates.
    Thompson PA; Berg SL; Aleksic A; Kerr JZ; McGuffey L; Dauser R; Nuchtern JG; Hausheer F; Blaney SM
    Cancer Chemother Pharmacol; 2004 Jun; 53(6):527-32. PubMed ID: 14997342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I Trial of G3139, a bcl-2 antisense oligonucleotide, combined with doxorubicin and cyclophosphamide in children with relapsed solid tumors: a Children's Oncology Group Study.
    Rheingold SR; Hogarty MD; Blaney SM; Zwiebel JA; Sauk-Schubert C; Chandula R; Krailo MD; Adamson PC;
    J Clin Oncol; 2007 Apr; 25(12):1512-8. PubMed ID: 17442993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Intrathecal infusion of the antineoplastic agents for meningeal dissemination].
    Hodozuka A; Hayashi Y; Annei R; Hiroshima S; Saito M; Orimoto R; Sato M; Tanaka T
    Gan To Kagaku Ryoho; 2008 Jun; 35(6):900-5. PubMed ID: 18633217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pharmacokinetic study of intra-CSF administered encapsulated cytarabine (DepoCyt) for the treatment of neoplastic meningitis in patients with leukemia, lymphoma, or solid tumors as part of a phase III study.
    Phuphanich S; Maria B; Braeckman R; Chamberlain M
    J Neurooncol; 2007 Jan; 81(2):201-8. PubMed ID: 16941075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I/II trial and pharmacokinetics of intrathecal diaziquone in refractory meningeal malignancies.
    Berg SL; Balis FM; Zimm S; Murphy RF; Holcenberg J; Sato J; Reaman G; Steinherz P; Gillespie A; Doherty K
    J Clin Oncol; 1992 Jan; 10(1):143-8. PubMed ID: 1727916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies.
    Mita MM; Mita AC; Chu QS; Rowinsky EK; Fetterly GJ; Goldston M; Patnaik A; Mathews L; Ricart AD; Mays T; Knowles H; Rivera VM; Kreisberg J; Bedrosian CL; Tolcher AW
    J Clin Oncol; 2008 Jan; 26(3):361-7. PubMed ID: 18202410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.